Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or in combination with chemotherapy. Promising results have previously been reported in nonrandomized studies in patients with chronic lymphocytic leukemia (CLL). This trial was designed to compare chemoimmunotherapy with chemotherapy alone in patients with previously treated CLL.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia, with an incidence of approximately two to four cases per 100,000 inhabitants per year in Western countries (Ͼ 20 per 100,000 after the age of 70 years). 1, 2 The disease generally follows an indolent course, with multiple relapses and remissions of decreasing quality and duration. Several prognostic factors have been identified, including disease stage, chromosomal aberrations (such as deletions of 17p, 13q, or 11q, or trisomy 12), immunoglobulin heavy-chain variable region (IgVH) mutational status, and overexpression of CD38 and/or the -chain-associated protein kinase 70 (ZAP-70). 3 CLL remains incurable with conventional chemotherapy, and new treatment options are needed. Apart from watchful waiting for patients with asymptomatic disease, several therapies are currently available, including alkylating agents (with or without corticosteroids) and purine nucleoside analogs, alone or in combination, for more advanced or symptomatic disease. Fludarabine has been shown to be superior to alkylating agent-based chemotherapy in patients with CLL, 4, 5 and combinations of fludarabine and cyclophosphamide (FC) have been shown to result in superior complete remission (CR) rates and duration of response (DR) compared with fludarabine alone. CD20 antigen on B lymphocytes, has activity in CLL as monotherapy [9] [10] [11] [12] [13] and in combination with chemotherapy. [14] [15] [16] [17] [18] [19] Some of the best phase II efficacy results have been produced with a combination of rituximab, fludarabine, and cyclophosphamide (R-FC) in both treatment-naïve 20, 21 and previously treated patients. 22 Twenty-five percent of previously treated patients achieved a CR with R-FC treatment. Of these patients, 12 (32%) achieved molecular remission in bone marrow. Compared with historical controls, CR rates and survival were significantly better with R-FC than with FC alone in both previously treated and untreated patients. 21, 23 The REACH (Rituximab in the Study of Relapsed Chronic Lymphocytic Leukemia) study (Roche Study No. BO17072; F. Hoffmann-La Roche, Basel, Switzerland) was initiated to directly compare R-FC with FC alone in patients with previously treated CLL.
PATIENTS AND METHODS

Study Design
This international, multicenter, open-label, phase III trial randomly assigned patients (1:1) with previously treated CLL to receive either R-FC or FC alone. Patients were stratified by country, previous treatment for CLL (alkylator refractory, alkylator sensitive, or fludarabine [or other nucleoside analog] exposed), time from diagnosis to random assignment (Ͻ 2, Ͻ 5, or Ͻ 10 years), and ␤ 2 -microglobulin (Յ upper limit of normal [ULN] or Ͼ ULN).
The primary objective was to demonstrate superior progression-free survival (PFS) for R-FC compared with FC alone. Secondary objectives were to compare event-free survival, disease-free survival, overall survival, overall response rate (ORR), CR rate, DR, molecular remission rate, time to new CLL treatment, safety, and quality of life (QOL) between the study arms and to characterize the pharmacokinetics of rituximab, fludarabine, and cyclophosphamide (data to be presented elsewhere). Evaluation of the relationship between baseline prognostic markers and clinical outcome in subsets of patients was also preplanned.
The study was conducted at 88 centers in 17 countries. All patients gave written informed consent, per Declaration of Helsinki recommendations. Safety and interim efficacy data were reviewed by an independent data safety monitoring board. F. Hoffmann-La Roche was the sponsor of the trial.
Eligibility Criteria
Patients age Ն 18 years with CD20 ϩ CLL according to National Cancer Institute Working Group criteria, 24 who had received one prior line of therapy, which could be single-agent chlorambucil (Ϯ prednisone/prednisolone), single-agent fludarabine (or other nucleoside analog), or an alkylatorcontaining combination regimen, but not an alkylator/nucleoside analog combination, were eligible. Patients could be sensitive or refractory to prior alkylating agents but had to be sensitive to fludarabine (defined as achieving a response that lasted Ն 6 months). Prior treatment with interferon, rituximab, other monoclonal antibodies, or stem-cell transplantation was not permitted.
Patients had to have adequate hepatic (bilirubin Ͻ 2ϫ ULN), renal (calculated creatinine clearance Ն 60 mL/min; 50 mL/min was permitted for a short period during the trial), and bone marrow function (neutrophils Ն 1 ϫ 10 9 /L; platelets Ն 50 ϫ 10 9 /L); an Eastern Cooperative Oncology Group performance status Յ 1; and a life expectancy of more than 6 months. Fertile patients had to use contraception. Exclusion criteria included transformation to aggressive B-cell malignancy; history of severe nucleoside analog-induced toxicity; clinically significant autoimmune hemolytic anemia; invasive malignancy in the last 2 years; other serious illness or medical conditions, including infection with HIV, hepatitis B or C, severe pulmonary or cardiac disease, recent myocardial infarction, uncontrolled diabetes or hypertension, seizure disorders requiring treatment, and comorbid conditions that might require systemic corticosteroids for more than 1 month; pregnancy or lactation; and recent use of other investigational drugs.
Study Treatment
Patients on both arms of the study received intravenous (IV) fludarabine 25 mg/m 2 /d and cyclophosphamide 250 mg/m 2 /d for 3 days, repeated every 28 days for a total of six cycles. Patients randomly assigned to rituximab received 375 mg/m 2 by IV infusion on day 1 of the first cycle (the day before chemotherapy) and 500 mg/m 2 IV on day 1 of subsequent cycles (the same day as chemotherapy), with premedication (oral acetaminophen and an antihistamine). Patients with an absolute lymphocyte count Ն 25 ϫ 10 9 cells/L before cycle 2 or subsequent cycles could have their rituximab dose split over 2 days, at the investigator's discretion.
Patients received supportive care as needed, including antibiotics, blood transfusions, and hematopoietic growth factors. Prophylaxis for tumor lysis syndrome (including allopurinol or rasburicase) and prophylactic antimicrobials (cotrimoxazole and acyclovir/valacyclovir) were required for all patients.
Chemotherapy dose reductions (Յ two permitted, each by 25%) and delays (of Ն 1 week) were scheduled for clinically significant grade 3 or 4 toxicities. Patients with renal impairment (creatinine clearance Ͻ 70 mL/min) also required a 25% dose reduction in fludarabine (discontinuation if the clearance decreased to Յ 30 mL/min).
Efficacy Assessments
Disease status was assessed by regular blood counts, clinical examination, and computed tomography (CT) scans throughout treatment and until 33 months after entering the study. Subsequent assessments were planned by clinical examination and blood counts every 6 months until 5 years, and then every year until 8 years. Response was assessed using the National Cancer Institute Working Group 1996 criteria, 24 with the addition of radiographs for assessment of best response and progression. Responses had to be confirmed with a CT scan Ն 8 weeks after first documentation of response, and CRs also required bone marrow biopsy confirmation. All CT scans and clinical efficacy data underwent an independent review (Perceptive Informatics, Boston, MA).
Molecular response was assessed in peripheral blood and bone marrow at the time of CR and 6 months later (if CR was maintained). Patients were categorized as molecular responders (minimal residual disease [MRD] negative) if there was no detectable clonal IgVH rearrangement, as assessed by polymerase chain reaction using standard methods and a sensitivity cutoff of 1 ϫ 10 Ϫ4 .
25,26
Safety and QOL Assessments Adverse events (AEs), assessed clinically and by laboratory measurements throughout the study, were graded according to the National Cancer Institute Common Toxicity Criteria (version 2.0). QOL was assessed at baseline, after three cycles and six cycles, and at 1 year using the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire (version 4.0).
Statistical Analysis
Recruitment of 550 patients was planned based on an estimated recruitment period of 55 months and a median PFS time of 20 months in the control arm. The sample size was required for 284 events to show a 40% improvement in median PFS (28 months) in the R-FC arm, corresponding to a 29% risk reduction (hazard ratio [HR] ϭ 0.714), with 80% power and an overall ␣ level of 5% (adjusted for one interim analysis after two thirds of the planned events).
All randomly assigned patients were included in the efficacy analyses, which were conducted on an intent-to-treat basis using investigator assessments of response/progression. Response rates were compared using 2 tests with 95% CIs applying the Anderson-Hauck method. Stratified and nonstratified log-rank tests and Cox regressions were used for time-to-event end points, with the median time calculated by Kaplan-Meier analysis. All statistical tests were two-sided. Exploratory analyses of prognostic factors were performed using logistic regression.
Safety data were summarized by grade, severity, and relationship to study medication, treatment arm, cycle, and phase; laboratory safety data were also summarized as shift tables. Additional safety analyses (not shown) were performed according to baseline characteristics (age, disease stage, creatinine clearance, and lymphocyte count).
QOL was analyzed by analysis of covariance, with treatment as the main factor and baseline FACT-G total score as a covariate. FACT-G subscores (eg, physical, social/family) and total score over time were also summarized descriptively.
RESULTS
Study Population
Between July 2003 and August 2007, 552 patients were enrolled and randomly assigned (n ϭ 276 per arm). Six randomly assigned patients (FC, n ϭ 4; R-FC, n ϭ 2) did not receive study treatment (Fig  1) . Table 1 lists the patients' baseline characteristics, which were well balanced in the two arms.
Treatment
More patients in the R-FC arm (67.5%) completed six cycles of therapy compared with the patients in the FC arm (61.4%; Fig 1) . Overall, most patients who stopped treatment early did so because of AEs, but more patients in the FC arm stopped as a result of insufficient response (stable or progressive disease) compared with R-FC arm (5% v 1%, respectively). More than 90% of patients received Ն 90% of the planned dose of fludarabine (25 mg/m 2 /d) and/or cyclophosphamide (250 mg/m 2 /d) in cycle 1, but this proportion decreased to approximately 67% for fludarabine and 73% for cyclophosphamide in cycle 4 and to 59% for fludarabine and 64% for cyclophosphamide in cycle 6. There were no major differences in FC exposure between the two arms. The vast majority of patients who received rituximab received more than 90% of the planned dose at each cycle, including 96% of patients in cycle 1.
The median follow-up time was 25 months. More patients in the FC arm (n ϭ 69, 25%) than in the R-FC arm (n ϭ 47, 17%) started a subsequent treatment for CLL. Of these patients, 49% in the FC arm and 30% in the R-FC arm received rituximab as part of their first subsequent treatment.
Safety and QOL
Almost all patients experienced AEs, but 70% of events in both arms were grade 1 or 2 in severity, and the proportions of patients who discontinued therapy as a result of an AE were similar in the two arms (Table 2) . Overall, the rates of AEs of any grade, grade 3 or 4 AEs, serious AEs, and fatal AEs were higher in the R-FC arm compared with the FC arm ( Table 2 ). More second malignancies (7% in R-FC arm v 5% in FC arm) and more cases of hepatitis B (primary infections and reactivation; 3% in R-FC arm v Ͻ 1% in FC arm) were also reported in the R-FC arm. Most fatal AEs (in both arms) were a result of infections. However, despite the higher rate of grade 3 or 4 neutropenia in the R-FC arm, the overall incidence of infections (51% in FC arm and 49% in R-FC arm) and grade 3 or 4 infections (19% in FC arm and 18% in R-FC) did not differ. This may have been a result of the greater use of colony-stimulating factors in the R-FC arm (58% v 49% in the FC arm) and mandatory antimicrobial and antiviral prophylaxis in both arms. The frequency and severity of AEs tended to be higher in older patients and patients with poor renal function in both arms of the study. In contrast to reports from previous single-arm studies, there was no apparent increase in toxicity with R-FC (notably, infusion-related events or tumor lysis syndrome) in patients with high baseline lymphocyte counts or advanced-stage disease (data not shown). The incidence and severity of rituximab infusion-related reactions were similar to those reported in patients with non-Hodgkin's lymphoma (NHL). Overall, R-FC was well tolerated.
QOL scores were high at screening (median score, 79.5 of 112 points and 80.0 of 112 points in the FC and R-FC arms, respectively) ‡CD38 was an optional assessment at baseline. and did not change substantially over the study period. Differences between treatment arms were small at every time point, with no apparent trends.
Efficacy
The primary end point of the study was PFS, which improved significantly in the R-FC arm compared with the FC arm, with an HR of 0.65 (representing a 35% reduction in risk of progression or death) and a 10-month improvement in median PFS time from 20.6 to 30.6 months (P Ͻ .001; Table 3 ; Figs 2A and 2B ). Significant improvements were observed in most secondary end points, including DR, time to new CLL treatment, CR, and ORR (Table 3) . These findings were supported by the results of the independent review committee (IRC; Table 3 ), which were also statistically and clinically in favor of the R-FC arm. With a median follow-up time of 25 months, there was no statistically significant difference in survival between the two treatment arms (Fig 2C) , although less than 10% of patients had died at this point.
MRD assessment was scheduled in patients achieving a CR. MRD results in peripheral blood were available for 32 of 39 patients for FC and 37 of 67 patients for R-FC. More patients receiving R-FC (16 [43%] of 37 patients) were MRD negative compared with patients receiving FC (10 [31%] of 32 patients). MRD in the bone marrow was assessed in only 12 patients (FC, n ϭ 4; R-FC, n ϭ 8), with no difference between the treatment arms.
The PFS (and ORR) benefit was consistent across key patient subgroups ( Figs 3 and 4 Abbreviations: FC, fludarabine and cyclophosphamide; R-FC, rituximab plus fludarabine and cyclophosphamide; HR, hazard ratio; NR, not reached; MRD, minimal residual disease.
‫ء‬ P values determined using the log-rank or 2 test. †P values determined using the Wald test. ‡Nonstratified (unadjusted). §Nonstratified (adjusted). Only in patients with a complete or partial response.
¶Only in patients with a complete response as assessed by the investigator.
DISCUSSION
The REACH study is the largest randomized trial in patients with previously treated CLL reported to date. The trial showed that the addition of rituximab to FC chemotherapy significantly improved PFS, a finding supported by the IRC analysis. Investigator-and IRCassessed CR rates were also significantly improved with R-FC, although CR rates reported by the IRC were much lower than those reported by the investigators. This was mainly because of the stringent IRC requirements for CT scan assessments, the need to follow strict algorithms without access to full clinical data (indicating, for example, transient or alternative reasons for changes in lymph node size or 001 1,092 1,183 1,274 1,365 1,456 1,547 1,638 1,729 A 0 Event-Free Rate 
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www.jco.org lymphocyte count), and lack of confirmatory bone marrow biopsies. The requirement for regular CT scans in this study went beyond the recognized requirements at the time 24 and more recent guidelines 27 and is not necessarily warranted in future studies or routine clinical practice.
Overall survival was not significantly improved in the R-FC arm. However, results were directionally consistent with the significant PFS benefit observed; the survival data were relatively immature; and posttrial cross over to rituximab had already occurred. Analysis of MRD was essentially inconclusive because of small patient numbers. Moreover, flow cytometry is now considered the method of choice for assessing MRD in CLL. 28 Other secondary efficacy end points were significantly better in the R-FC arm than the FC arm, and subgroup analyses also showed consistent trends in efficacy in almost all of the prespecified subgroups tested. In particular, R-FC was beneficial in patients with all disease stages and in some particularly poor prognosis subgroups (notably patients with unmutated IgVH, with del11q, and positive for ZAP-70). These findings from a randomized, international, multicenter study confirm the positive findings from singleinstitution phase II trials of R-FC in patients with previously treated CLL 22, 23 and phase II and III trials of R-FC in patients with newly diagnosed CLL, 20, 21, 29, 30 indicating that R-FC provides the longest PFS of any regimen yet tested in patients with CLL.
These findings are supported by evidence from many phase II CLL studies showing the efficacy of rituximab in combination with chemotherapy regimens other than FC, including fludarabine [14] [15] [16] and fludarabine-based regimens [31] [32] [33] [34] ; pentostatin-and cladribinebased regimens 18, 19, 35, 36 ; cyclophosphamide, doxorubicin, vincristine, and prednisone 37 ; bendamustine 17 ; alemtuzumab 38 ; and high-dose corticosteroids. 39, 40 These phase II studies demonstrate consistently high ORRs and CR rates, generally in the range 70% to 95% and 0% to 43%, respectively, in previously treated patients and more than 90% and more than 40%, respectively, in previously untreated patients. Administration of rituximab in combination with FC chemotherapy was well tolerated, consistent with the known safety profile of rituximab. Although grade 3 or 4 neutropenia was more frequent in the R-FC arm, there was no increase in overall or severe infections or the proportion of patients who had to stop treatment early as a result of toxicity, and the addition of rituximab had no detrimental effect on QOL. Second malignancies were reported more frequently in the R-FC arm, but a variety of neoplasms were reported with no predominant type, and there was no increase in myelodysplastic syndrome or related hematologic malignancies. Patients with CLL are known to be at increased risk of second malignancies, and a recent large study showed no increase in the incidence of second malignancy in patients with CLL treated with rituximab-based regimens.
41
The R-FC regimen used in this study was developed by Keating et al 20 and Wierda et al 22 and includes a higher dose of rituximab (500 mg/m 2 in cycles 2 to 6) than used in patients with NHL. The decision to use a higher dose of rituximab was based on phase II data that demonstrated superior efficacy in patients with relapsed CLL treated with higher doses of rituximab monotherapy. 10 Rituximab had also been observed to have poorer efficacy in patients with CLL or small lymphocytic lymphoma 9, 13 and to result in lower serum levels of rituximab compared with patients with follicular NHL. 13, 42 This phenomenon is thought to be related to increased CD20 antigenemia and/or higher levels of circulating tumor cells in patients with CLL. 43 Because of general European practice at the time of recruitment, only a minority of patients in the REACH study had previously been exposed to fludarabine during their initial therapy for CLL. This may be a limitation of the study because purine analog combinations are now more widely used as first-line therapy. 44 However, the results of R-FC treatment in the subgroup of fludarabine-exposed patients were consistent with the benefits seen in the study overall (Fig 3) .
Overall, the results of the REACH study indicate that R-FC is efficacious and well tolerated and that it is an important treatment option for patients with previously treated CLL. These findings are consistent with recent results showing that R-FC is superior to FC when used as initial treatment for patients with CLL. Hazard ratios and 95% CIs for progression-free survival (PFS) by subgroup (intent-to-treat population, investigator assessment). PFS was measured from day of random assignment until first documented disease progression, relapse after response, or death from any cause. Censoring occurred at last response assessment. IgVH, immunoglobulin heavy-chain variable region; ZAP-70, zeta-chain-associated protein kinase 70.
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